EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieMultizentrische StudieOpen Access · CC BY 4.0

Comparison of early treatment with ceftolozane/tazobactam versus polymyxin-based therapy of pneumonia due to MDR Pseudomonas aeruginosa (PUMA)

Thomas P Lodise iD, Jae Min, Brian H Nathanson, Emre Yücel

Antimicrobial Agents and Chemotherapy · 05.11.2025 · 69 (11)

DOI: 10.1128/aac.00569-25 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.11.2025. Verfasst von Thomas P Lodise und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Cephalosporins, Pneumonia, Bacterial, Polymyxins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ceftolozane/tazobactam and polymyxin-based regimens are frequently used to treat pneumonia caused by multi-drug-resistant P. aeruginosa (MDR-PSA). However, comparative data on global clinical outcomes between these therapies are limited. A multi-centered observational study was performed using the PINC AI TM Healthcare Database (2016–2022). The study population included hospitalized patients ≥ 18 years who were diagnosed with pneumonia and had MDR-PSA (defined as non-susceptible to ≥1 agent in ≥3 antimicrobial categories) on a respiratory or blood culture, receipt of ceftolozane/tazobactam or a polymyxin-based regimen within 3 days of index MDR-PSA culture, receipt of ≥2 days of ceftolozane/tazobactam or a polymyxin-based regimen, and without a COVID-19 diagnosis. A Desirability of Outcome Ranking (DOOR) analysis was performed. Components of the DOOR included in-hospital mortality, discharge destination (home vs other), recurrent MDR-PSA pneumonia, receipt of any renal replacement therapy (RRT) post-index culture in RRT-naive patients, and 30-day pneumonia-related readmissions. In total, 186 patients met the study criteria (104 ceftolozane/tazobactam and 82 polymyxin). In the IPW-adjusted DOOR analysis, a ceftolozane/tazobactam-treated patient had a higher probability of a more favorable outcome (DOOR probability: 61.3%; 95% CI: 56.8%, 65.7%). In the DOOR partial credit analyses, a ceftolozane/tazobactam-treated patient had a higher probability of being discharged home alive with no undesirable outcomes than a polymyxin-treated patient (20.2% vs 9.8%, P = 0.04). This real-world evidence study of non-COVID-19 patients with MDR-PSA pneumonia suggests that patients treated with ceftolozane/tazobactam have a higher probability of a more favorable outcome compared with patients treated with a polymyxin-based regimen. Further large-scale studies with detailed dosing are needed to validate the findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsCephalosporinsPneumonia, BacterialPolymyxinsPseudomonas aeruginosaPseudomonas InfectionsTazobactamAgedAged, 80 and overFemaleHumansMaleMiddle AgedCOVID-19Drug Resistance, Multiple, BacterialTreatment Outcome

Stichwörter der Autor:innen

DOORPseudomonasceftolozane/tazobactamoutcomespolymyxin

Substanzen

Anti-Bacterial Agentsceftolozane, tazobactam drug combinationCephalosporinsPolymyxinsTazobactam

Autor:innen und Institutionen

  • Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
  • Merck & Co., Inc., Rahway, New Jersey, USA.
  • OptiStatim LLC, Longmeadow, Massachusetts, USA.

ORCID-Profile: Thomas P Lodise

Förderung

  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

Zitieren

APA

Lodise, T. P., Min, J., Nathanson, B. H., & Yücel, E. (2025). Comparison of early treatment with ceftolozane/tazobactam versus polymyxin-based therapy of pneumonia due to MDR Pseudomonas aeruginosa (PUMA). Antimicrobial Agents and Chemotherapy, 69(11). https://doi.org/10.1128/aac.00569-25

Vancouver

Lodise TP, Min J, Nathanson BH, Yücel E. Comparison of early treatment with ceftolozane/tazobactam versus polymyxin-based therapy of pneumonia due to MDR Pseudomonas aeruginosa (PUMA). Antimicrobial Agents and Chemotherapy. 2025;69(11). doi:10.1128/aac.00569-25

BibTeX
@article{Lodise2025,
  author = {Lodise, Thomas P and Min, Jae and Nathanson, Brian H and Yücel, Emre},
  title = {Comparison of early treatment with ceftolozane/tazobactam versus polymyxin-based therapy of pneumonia due to MDR Pseudomonas aeruginosa (PUMA)},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  volume = {69},
  number = {11},
  doi = {10.1128/aac.00569-25}
}
Kostenlos starten →